Cytel expands its advanced real-world analytics capabilities with acquisition of MTEK Sciences

Cytel Inc. (“Cytel” or the “Company”), the leading provider of innovative analytical software and consulting services to the biopharmaceutical sector, and a portfolio company of New Mountain Capital, today announced that it has acquired MTEK Sciences (“MTEK”) to further expand its advanced real-world analytics (RWA) capabilities. Cytel is showcasing its extensive range of RWA solutions for the first time at ISPOR Europe 2019 (November 2–6) on booth #C3-063. The acquisition of MTEK is the latest step in Cytel’s journey to advance the field of modern data analytics.

Cytel expands its advanced real-world analytics capabilities with acquisition of MTEK Sciences
Joshua Schultz, Chief Executive Officer of Cytel

The use of real-world data (RWD) from a variety of sources, such as information from electronic healthcare records and wearable devices, has the potential to expedite the design and implementation of clinical trials, facilitate product commercialization and better inform healthcare decision-making. As a result, many pharmaceutical companies are now looking to augment their clinical development and commercialization processes through its utilization.

Complex RWD sets are now abundant in the healthcare sector, opening up a wealth of opportunity for pharmaceutical organizations of all sizes. Advanced and more sophisticated analytical methods and decision-modeling techniques are needed to harness RWD and turn it into trustworthy evidence. At Cytel, we’re applying our long history of innovative statistical methods to RWD to generate cost-effective insights for our clients, and the acquisition of MTEK is another avenue where we are amplifying this approach.”

Joshua Schultz, CEO at Cytel

Over the past 30 years, Cytel has been committed to facilitating more efficient and resourceful clinical development, including through pioneering the evolution of the adaptive clinical trial, an area MTEK has also excelled at. Cytel’s team includes more than 100 specialist programmers and applied statisticians with direct experience in the area of RWA — from HEOR to the design of novel RWD-driven clinical trials. Together they are helping companies use RWD to support smarter clinical development and, through innovative approaches to comparative effectiveness research, create more efficient commercialization strategies.

MTEK Sciences specializes in using innovative methods such as machine learning models and Bayesian optimization to derive clinical insights from large and complex RWD. As such, the acquisition of the firm will allow Cytel to continue to build on its strong foundation in the RWA space.

Professor Edward Mills, Founding Partner and Director of MTEK, said:

Our experience has shown us that companies need to look beyond the confines of traditional analytical approaches if RWD is to positively transform clinical development. In working with Cytel, we're enhancing our combined ability to develop and deploy the novel solutions needed to confidently guide companies through this rapidly changing landscape.”

Professor Kristian Thorlund, Founding Partner and Director of MTEK Sciences, added:

Cytel and MTEK have a tightly aligned vision for the future of RWD applications. Combining our comprehensive statistical know-how means we can deliver greater innovation to a wider array of companies as they seek to enrich their drug development process with RWD.”

Commenting on Cytel’s attendance at ISPOR Europe 2019, Joshua Schultz added:

Three decades of rich statistical expertise and experience has guided the development of our cutting-edge RWA solutions — and we look forward to meeting with delegates to discuss how we can help them effectively leverage these to achieve their goals.”

Source:

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Cytel. (2019, November 08). Cytel expands its advanced real-world analytics capabilities with acquisition of MTEK Sciences. News-Medical. Retrieved on November 13, 2019 from https://www.news-medical.net/news/20191108/Cytel-expands-its-advanced-real-world-analytics-capabilities-with-acquisition-of-MTEK-Sciences.aspx.

  • MLA

    Cytel. "Cytel expands its advanced real-world analytics capabilities with acquisition of MTEK Sciences". News-Medical. 13 November 2019. <https://www.news-medical.net/news/20191108/Cytel-expands-its-advanced-real-world-analytics-capabilities-with-acquisition-of-MTEK-Sciences.aspx>.

  • Chicago

    Cytel. "Cytel expands its advanced real-world analytics capabilities with acquisition of MTEK Sciences". News-Medical. https://www.news-medical.net/news/20191108/Cytel-expands-its-advanced-real-world-analytics-capabilities-with-acquisition-of-MTEK-Sciences.aspx. (accessed November 13, 2019).

  • Harvard

    Cytel. 2019. Cytel expands its advanced real-world analytics capabilities with acquisition of MTEK Sciences. News-Medical, viewed 13 November 2019, https://www.news-medical.net/news/20191108/Cytel-expands-its-advanced-real-world-analytics-capabilities-with-acquisition-of-MTEK-Sciences.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post